ArticleCureus2026
Molecular Diagnosis in Patients With Tuberous Sclerosis Complex: A Deep Sequencing Approach in Clinical Practice.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Tuberous sclerosis complex (TSC) is an autosomal dominant neurocutaneous disorder caused by pathogenic variants in TSC1 or TSC2. Despite established clinical diagnostic criteria, a subset of patients remains molecularly unsolved after conventional genetic screening, often due to deep intronic variants, structural anomalies, or low-level somatic mosaicism. Methods A retrospective cohort study was performed. Patients without an identified pathogenic variant after conventional Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA) were selected for targeted high-depth next-generation sequencing (NGS), achieving a median sequencing depth of at least 800×. Clinical data were collected for phenotypic characterization. Results High-depth targeted sequencing identified pathogenic or likely pathogenic variants in the TSC2 gene in four out of seven previously unresolved patients, resulting in an incremental diagnostic yield of 57.1% (4/7). The identified variants were deep intronic structural alterations or splice-modifying changes (c.2838-122G>A, c.848+281C>T, and c.2640-16_2640-8del). Two unrelated patients carried the identical c.848+281C>T deep intronic variant. Patients with identified TSC2 variants exhibited a high prevalence of structural central nervous system anomalies, epilepsy, and multi-system tumor involvement compared to the molecularly unconfirmed subgroup. Discussion High-depth targeted sequencing using hybrid-capture enrichment provides a substantial diagnostic advantage for detecting deep intronic variants in previously unsolved TSC cases. These findings advocate for integrating deep sequencing into clinical practice. Although TSC remains mainly a clinical diagnosis, identifying pathogenic variants has an important role in diagnosing patients who do not meet complete clinical criteria, in providing genetic counseling, as well as access to potential targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.